Today’s AI Top Pick: ALNY

7/31/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianALNYBUY NOW8.7 / 107/31/2026

Alnylam is the cleanest multi-timeframe contrarian bounce setup in the pool. Every single timeframe forecasts up: 1h +49.1%, 4h +46.7/+56.9/+79.2%, 1d +54.5/+82.9/+70.5%, and 1wk +3.7/+11.6/+10.3% — no timeframe dissents, which is rare here (SPRO, AAON, REPL all have bearish weekly forecasts). Bullish probability is 1.0 and near_term_bullish is 1.0. RSI is 23.5, deeply oversold. Position in the 21-bar range is basically at the floor across every TF (0.86 on 1d, 0 on 1wk, 4.5 on 4h) so we are absolutely NOT chasing — we are buying capitulation, not strength. Fundamentals are the best in the pool alongside SPRO (fundamental_score 8). ROE 96.9%, gross margin 80.8%, operating margin 17.5%, salesYoY +82.6%, PEG 0.26, fwd P/E 20.6, epsNextY +42.6%, analyst recom 1.67, targetUpsidePct +95.5%. This is a real $27B cap franchise, not a lottery ticket like NIXX, INDP, or LNAI. The 14-day drawdown of -23% has come with confirmed positive news: Q2 2026 earnings just posted with Amvuttra crossing the $1B annualized threshold — the sell-off is a valuation reset on a growth cadence, not a broken business. Why today rather than wait: the setup checks the classic exhausted-selling boxes — oversold RSI, position at the very bottom of the 21-bar range on 3 of 4 TFs, all forecasts flipping bullish including the previously bearish weekly, and a fresh positive earnings catalyst that the market hasn't repriced yet. Waiting for confirmation typically costs 5-10% in a name like this once the algorithmic short-cover starts. Contrast with EVH (Cowen/Citi cuts, PT to $5), LII (guidance cut), TDOC (Q2 miss), REPL (FDA reviewers doubt RP1) — those are broken theses; ALNY is a quality name in an oversold air pocket with a positive print. SPRO is the closest #2 on fundamentals (fund score 8, Innovent $1.1B licensing deal) but its weekly forecast is -20% to -30% and it's a $69M micro-cap where a single trial headline can vaporize the position. ADTN is #3 with clean multi-TF alignment but weaker fundamentals and PT cuts. ALNY offers the best risk-adjusted asymmetry.

Entry zone

$204-$210 (current $206.50, add on any dip toward $200 which is near the 21-bar low)

Stop loss

$188 (below the 4h/1d low, ~9% risk — a break there confirms fresh downtrend and invalidates the exhausted-selling thesis)

First target

$240-$250 (aligns with 1d fc_short +54% would overshoot; realistic first stop into the gap fill zone, ~16-21% upside)

Longer target

$310-$330 (matches 1d fc_mid +82.9% and analyst targetUpsidePct +95.5%, ~50-60% swing target over 8-12 weeks)

Risks

Weekly forecast is only modestly positive (+3.7% to +11.6%) — the longer structural downtrend from -34% weekly move isn't fully broken
Debt/Equity of 2.76 is elevated for biotech; any Amvuttra guidance disappointment on next call could re-accelerate selling
Position at 0-6.9% of 21-bar range means the stock is still making lows — knife-catching risk if $200 breaks, next support ~$185
Sector rotation risk: healthcare/biotech has been weak (perfYear -39.5% for ALNY), broader group could remain a headwind
P/E of 48.8 is not cheap on trailing basis; a growth stumble would compress the multiple meaningfully

Honorable mentions

SPROSame fundamental_score 8, licensing deal with Innovent worth up to $1.1B, deep-value fwd P/E 1.79, 1h/4h/1d forecasts all strongly bullish (+120/+108/+19-103%). Downgraded to #2 because weekly forecast is negative (-20 to -30%) and $69M micro-cap adds binary event risk.

ADTNClean multi-TF alignment (1h +81%, 4h +38-61%, 1d +6-23%, 1wk flat), position at 4.8-5.6% of 21-bar range, PEG 0.17, salesYoY +18.8%. Recent PT cuts from B.Riley and Needham (but both maintain Buy) is the main hesitation.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	ALNY	BUY NOW	8.7	All 4 timeframes bullish, position at range floor, fund score 8, Q2 print with Amvuttra >$1B — best risk-adjusted bounce in the pool.
2	SPRO	BUY NOW	7.8	Fund score 8, Innovent $1.1B licensing catalyst, deep-value fwd P/E 1.79 — knock is bearish weekly forecast and micro-cap risk.
3	ADTN	BUY NOW	7.2	Multi-TF bullish (1h +81%, 4h +61%, 1d +23%), PEG 0.17, oversold at bottom of range.
4	AAON	BUY PULLBACK	6.5	Quality Industrials with data-center cooling tailwind, but 1d forecasts only +0.6/+3.9/+5.6% and weekly slightly negative.
5	PSN	BUY PULLBACK	6.3	All TFs bullish with 1d fc_mid +50.5%, but 1h already at 100% of range and three analyst PT cuts on same day.
6	NAUT	BUY PULLBACK	5.9	Massive forecasts across TFs (1h/4h +115-130%), oversold RSI 20.6, but fund score -0.5 and P/S 690 make it speculative.
7	NXL	WAIT	5.4	All TFs bullish with 1d fc_long +92%, but $7.5M micro-cap with -3022% profit margin — pure lottery ticket.
8	ACDC	BUY PULLBACK	5.3	Strong 1h/4h forecasts (+116/+53%), but energy services softness and negative fund score.
9	CNCK	WAIT	5.2	Weekly forecast +474% is eye-catching plus positive Bhutan mandate news, but fwd P/E 1363 and thin coverage.
10	CVLT	WAIT	5.0	Solid fund score 6.25 and Zacks upgrade, but 1d/1wk forecasts near zero or negative — no bounce conviction from the model.
11	INDP	WAIT	4.8	1wk fc_long +615% is compelling but 1h forecasts turn negative and it's a $163M clinical-stage biotech with roe -932%.
12	TVRD	WAIT	4.6	BTIG maintains Buy at $5 PT and forecasts are bullish, but ATM offering announced and revenue -100% YoY.
13	GXAI	WAIT	4.5	All TFs bullish with big magnitudes, oversold RSI 18.8, but $8.5M cap and post-divestiture strategy still unfolding.
14	NIXX	WAIT	4.4	1h fc turns negative and no weekly data; Nakota project news is positive but $16M cap is too thin for size.
15	LODE	WAIT	4.3	Modest forecasts, fund score 0, salesYoY -69% — Q2 earnings didn't provide clear catalyst.
16	AKTX	WAIT	4.0	1d fc_long +164% but weekly forecast is -100% (model flagging binary risk) — dangerous to trust the bounce.
17	HSCS	WAIT	3.9	Bullish 4h/1d forecasts but pivoting to a Zcash mining merger — thesis is completely different now, unpredictable.
18	ACI	WAIT	3.9	EVP insider buy of $1.96M and bullish forecasts, but no weekly TF data and fund score -1 with margin 0.08%.
19	CANG	AVOID	3.6	Just executed 1-for-10 reverse split for NYSE compliance — 1h/4h forecasts are -64%/-42% short-term, wait for base.
20	REPL	AVOID	3.5	FDA reviewers cited efficacy concerns on RP1 melanoma drug; every TF forecasts -35% to -47%, at 100% of range — chase risk.
21	OTLK	AVOID	3.3	FDA approval already priced in and 1h/4h forecasts -64% to -70% — sell-the-news setup, not a bounce.
22	EVH	AVOID	3.2	TD Cowen cut PT to $5, Citi downgrade, 'nosediving' headline — broken thesis regardless of forecast.
23	MNRO	AVOID	3.1	Q1 miss, Stephens cut PT to $17, 1h at 100% of range — no margin of safety on entry.
24	LII	AVOID	2.9	Explicit Q2 guidance cut — the down move is fundamental, not a technical dip.
25	TDOC	AVOID	2.8	Q2 disappointment, fund score -1.5, forecasts near flat (+1.5 to +4.6%), targetUpsidePct only 18.4%.
26	LNAI	AVOID	2.5	Weekly forecast -100%, fund score -2.5, profit margin -612,568% — untradeable dumpster fire.
27	AIFA	AVOID	2.4	Only 1d/1wk data available, fund score 0, $9.8M cap with profitMargin -457% — pure gamble.
28	AIIO	AVOID	2.2	Fund score -3.25, salesYoY -92%, operMargin -16,692% — no thesis regardless of near-term chart.
29	PMEC	AVOID	2.1	Fund score -2.5, $15M cap, no analyst coverage or weekly TF — nothing to lean on.
30	GLE	AVOID	1.9	Fund score -3, salesYoY -76%, $5.8M shell-like cap — avoid.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord